GlassScriptPhysician profile
Joseph P Jiang
NPI 1801909759
$1,576.06
in general payments reported to CMS, 2019-2025
24 companies · $197 in 2025
The $197 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10.93 · 2020: $39.00 · 2021: $435 · 2022: $454 · 2023: $296 · 2024: $144 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $636.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $392.27 | 2021-2023 | Repatha |
| Pfizer INC. | $191.40 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $191.16 | 2022-2024 | |
| Novo Nordisk INC | $146.03 | 2021-2023 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.64 | 2021-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $79.82 | 2020-2021 | |
| Rigel Pharmaceuticals, INC. | $55.45 | 2022 | |
| Becton, Dickinson and Company | $46.94 | 2021-2022 | |
| Edwards Lifesciences Corporation | $45.23 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Tandem Diabetes Care, INC. | $40.14 | 2022 | |
| Madrigal Pharmaceuticals | $38.14 | 2025 | Rezdiffra |
| Corcept Therapeutics | $25.25 | 2021 | |
| Sobi, INC | $24.71 | 2024 | |
| Dexcom, INC. | $24.22 | 2024 | Dexcom G6 Transmitter |
| Baxter Healthcare | $24.05 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $23.73 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $20.92 | 2023 | Arcalyst |
| Esperion Therapeutics, INC. | $19.50 | 2024 | Nexletol |
| Lilly USA, LLC | $18.87 | 2025 | Mounjaro |
| Abbvie INC. | $18.52 | 2021 | |
| Ibsa Pharma INC. | $16.84 | 2022 | |
| Dova Pharmaceuticals | $14.31 | 2021 | |
| Medtronic Minimed, INC. | $13.99 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Jiang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.